Novo Nordisk stock (NVO) (DK:NOVO.B) slumped 21.83% to fall to a new three-year low. It was the stock's worst daily loss since a 26.15% fall on Oct. 19, 1987. It's fallen 24.77% over the past two days ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

By Patrick Wingrove and Bhanvi Satija (Reuters) -Investors and analysts say they expect Eli Lilly to report stronger ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

Novo, which became Europe’s most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as ...

A major Alzheimer’s disease medical group is recommending that specialists may use certain blood tests to help diagnose ...

Pedersen, Stine Jacobsen and Maggie Fick COPENHAGEN (Reuters) -Investors wiped $70 billion off Novo Nordisk's market value on ...

Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

Facing a $70 billion market loss, Novo Nordisk appointed Maziar Mike Doustdar as its new CEO to navigate intensifying ...

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.